FDA Warning Letters Issued in August 2026: Complete Published List and Key Findings

Suggested SEO title: August 2026 FDA Warning Letters: 30 Published Cases by Sector
Suggested meta description: See all 30 FDA warning letters dated August 2026 and published by September 23, with direct FDA links and a grounded review of drug, device, food, biologics, import, animal food, and tobacco issues.
Reviewed: September 23, 2026

FDA’s public warning-letter database listed 30 letters with issue dates from August 1 through August 31, 2026, as of September 23, 2026. This article summarizes that full published set. FDA sometimes posts a letter weeks after its issue date, so the list and totals may change. The count refers to the letters in this database, not every regulatory action FDA took in August or separate tobacco retailer notices.

The letters span seven issuing offices. They cannot all be described as drug cGMP or inadequate Form 483 responses: some concern website drug claims, imported food verification, clinical research, animal food, medical device reporting, and tobacco products.

Issuing office	August-dated letters
Center for Drug Evaluation and Research (CDER)	16
Office of Inspections and Investigations	4
Center for Biologics Evaluation and Research (CBER)	2
Center for Devices and Radiological Health (CDRH)	2
Human Foods Program	2
Center for Veterinary Medicine (CVM)	2
Center for Tobacco Products (CTP)	2
Total	30

What Stands Out in the August Letters

Drug manufacturing and marketed product risk

Eleven of CDER’s 16 letters are classified in FDA’s listing under finished-drug or active-pharmaceutical-ingredient cGMP, sometimes alongside other issues. For example, FDA’s August 25 letter to Fresenius discusses investigations of leaking peritoneal dialysis solution bags, risk to distributed product, corrective actions, and qualification of visual inspectors. Its August 12 letter to K.C. Pharmaceuticals addresses aseptic processing, media fills, airflow studies, retrospective product assessment, stability, and laboratory controls. These are examples from the set; their findings should not be projected onto all 30 letters.

Peptide marketing claims

Five CDER letters dated August 24 concern firms selling peptide products that FDA identified as unapproved new drugs and misbranded products in its database. The Peptide Partners letter explains FDA’s assessment of the website’s product claims and its conclusion that a “research use only” statement did not resolve the intended-use concerns described in that letter. These letters are distinct from inspection-based cGMP findings.

Food, supplements, and imports

The one dietary supplement letter in this published August set is to BioDrive. It concerns FDA’s assessment of the safety evidence for a new dietary ingredient, not a cited pattern of missing identity tests under 21 CFR Part 111. In the other Human Foods Program letter, FDA describes cooling, sanitation, and related controls at Binh Minh Tofu. Four separate letters issued by the Office of Inspections and Investigations carry FDA’s Foreign Supplier Verification Program (FSVP) subject classification for food importers.

Medical devices, biologics, animal food, and tobacco

The two device letters concern different issues: FDA describes device premarket authorization concerns at Advance-Esthetic and medical device reporting procedures at Lion Street Medical/Pensar Medical. Neither is classified by FDA’s listing as a device QMSR letter.

CBER’s two letters address clinical study oversight at Stephen J. Fallon, Ph.D. and unapproved drug/unlicensed biological product issues at R3 Medical Companies. CVM issued two animal-food letters; Viva Raw discusses FDA’s concerns following samples found to contain Salmonella or Listeria monocytogenes. CTP issued two tobacco-product letters.

Complete List: Letters Dated August 2026

The descriptions below are FDA’s listing categories condensed for readability, not a complete account of each letter’s findings. Select a company name to read the primary document. Listed by issue date, most recent first.

Issue date	Recipient	FDA issuing office	Listed subject
08/27/2026	Jabil Inc.	Drug center (CDER)	Finished drug cGMP
08/27/2026	Stephen J. Fallon, Ph.D.	Biologics center (CBER)	Clinical study oversight
08/27/2026	Union Trade Inc.	Office of Inspections and Investigations	FSVP importer
08/25/2026	Fresenius Medical Care AG & Co. KGaA	Drug center (CDER)	Finished drug cGMP
08/25/2026	Advance-Esthetic LLC	Device center (CDRH)	Device premarket authorization
08/24/2026	Peak Performance Peptides	Drug center (CDER)	Unapproved/misbranded drugs
08/24/2026	Royal Peptides LLC	Drug center (CDER)	Unapproved/misbranded drugs
08/24/2026	NuScience Peptides LLC	Drug center (CDER)	Unapproved/misbranded drugs
08/24/2026	Peptide Partners LLC	Drug center (CDER)	Unapproved/misbranded drugs
08/24/2026	TXP Innovations LLC dba Tex Peptides	Drug center (CDER)	Unapproved/misbranded drugs
08/24/2026	BioDrive, Inc.	Human Foods Program	Dietary supplement
08/21/2026	Raaw Energy LLC	Veterinary center (CVM)	Animal food
08/21/2026	Lion Street Medical, d/b/a Pensar Medical LLC	Device center (CDRH)	Medical device reporting
08/18/2026	Reliance Life Sciences Private Limited	Drug center (CDER)	Finished drug cGMP
08/18/2026	Shoolin Pharma Chem LLP	Drug center (CDER)	API cGMP
08/18/2026	B&P Mutual Corp	Office of Inspections and Investigations	FSVP importer
08/18/2026	PReye, LLC	Drug center (CDER)	Finished drug cGMP; unapproved drug
08/18/2026	Binh Minh Tofu	Human Foods Program	Human food controls
08/14/2026	R3 Medical Companies	Biologics center (CBER)	Unapproved drugs; unlicensed biologics
08/13/2026	Suretec Innovations, LLC	Drug center (CDER)	Finished drug cGMP; misbranding
08/13/2026	Eugia Pharma Specialities Limited	Drug center (CDER)	Finished drug cGMP
08/12/2026	K.C. Pharmaceuticals, Inc.	Drug center (CDER)	Finished drug cGMP
08/12/2026	Auriga Research Pvt. Ltd.	Drug center (CDER)	Finished drug cGMP
08/07/2026	giantnic.com	Tobacco center (CTP)	Tobacco product violations
08/07/2026	Safrel Pharmaceuticals LLC	Drug center (CDER)	Finished drug cGMP
08/07/2026	mikuvape.com	Tobacco center (CTP)	Tobacco product violations
08/06/2026	Tianjin Kilo Pharmaceutical Sci-tech Co., Ltd.	Drug center (CDER)	CGMP/Active Pharmaceutical Ingredient (API)/Adulterated/Misbranded
08/05/2026	Quantum Star LLC	Office of Inspections and Investigations	FSVP importer
08/05/2026	Viva Raw LLC	Veterinary center (CVM)	Animal food
08/04/2026	Mesquite Gourmet LLC	Office of Inspections and Investigations	FSVP importer

How to Use This Review

For a facility responding to an inspection, start with the actual observations and underlying records. Where relevant, assess the potential impact on previously released product, test whether a proposed corrective action addresses the cause, and document how the change will be verified. For a firm facing a website-claims, FSVP, reporting, or premarket issue, follow the requirements and response instructions applicable to that specific letter.

FDA’s draft guidance on Form FDA 483 responses after drug cGMP inspections says a response to the observations is not required but recommends submission within 15 business days if an establishment chooses to respond, so FDA can consider it before deciding on further action. A warning letter can request its own response within a stated period. Check the document you received; there is no single “mandatory 15-day Form 483 response” rule covering all the cases above.

Method: We reviewed the FDA public warning-letter listing, sorted by Letter Issue Date, and included entries dated August 1–31, 2026 that were available September 23, 2026. We counted each listing once and grouped by FDA issuing office. FDA may add an August-issued letter later or update the status of a listed matter. Consult the linked letters and FDA’s current listing before relying on a case’s status.

Need help reviewing an FDA document? Call FDAInspections.com at (888) 781-1822 to discuss the findings, response instructions, and technical work needed.

This review is general educational information based on FDA’s public records. A warning letter describes FDA’s position when issued; later correspondence or corrective action may change the regulatory status of a matter.